Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center

Kyuhwan Jang,1 Jayoung Ahn,1 Joonhong Sohn,1 Daniel Duck-Jin Hwang1,2 1Department of Ophthalmology, HanGil Eye Hospital, Incheon, Korea; 2Department of Ophthalmology, Catholic Kwandong University College of Medicine, Incheon, KoreaCorrespondence: Daniel Duck-Jin HwangDepartment of Ophthalmology, Han...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jang K, Ahn J, Sohn J, Hwang DDJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	anti-vascular endothelial growth factor bilateral intravitreal injection bevacizumab aflibercept ranibizumab safety Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6c366e83ca8148b9b6d727ae156d86af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c366e83ca8148b9b6d727ae156d86af
record_format	dspace
spelling	oai:doaj.org-article:6c366e83ca8148b9b6d727ae156d86af2021-12-02T12:51:03ZEvaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center1177-5483https://doaj.org/article/6c366e83ca8148b9b6d727ae156d86af2020-10-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-the-safety-of-bilateral-same-day-intravitreal-injections-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kyuhwan Jang,1 Jayoung Ahn,1 Joonhong Sohn,1 Daniel Duck-Jin Hwang1,2 1Department of Ophthalmology, HanGil Eye Hospital, Incheon, Korea; 2Department of Ophthalmology, Catholic Kwandong University College of Medicine, Incheon, KoreaCorrespondence: Daniel Duck-Jin HwangDepartment of Ophthalmology, HanGil Eye Hospital, #35 Bupyeong-Daero, Bupyeong-Gu, Incheon 21388, KoreaTel +82-32-503-3322Fax +82-32-504-3322Email daniel.dj.hwang@gmail.comPurpose: To evaluate the short-term ophthalmic side effects of bilateral same-day intravitreal anti-vascular endothelial growth factor (VEGF) injections.Patients and Methods: We retrospectively analyzed patients who received intravitreal bevacizumab, ranibizumab, and aflibercept injections in both eyes on the same day between January 2014 and June 2019. The patients were followed up for 1 day, 1 week, and 1 month after the injections.Results: A total of 323 patients (646 eyes) received 1418 bilateral same-day intravitreal anti-VEGF injections. The patients’ mean age was 62.47 ± 13.97 years. The most common cause of bilateral injection was age-related macular degeneration (54.80%), followed by complications due to diabetic retinopathy (35.33%), retinal vein occlusion (2.40%), and central serious chorioretinopathy (1.27%). There were 22 cases of subconjunctival hemorrhage, 17 cases of temporary elevation of intraocular pressure, and no case of endophthalmitis. Twenty-one patients showed acute intraocular inflammation after the bilateral injection. All patients showed complete improvement within 2 weeks after the injection.Conclusion: Bilateral same-day intravitreal anti-VEGF injection is a well-tolerated procedure on short-term follow-up. It is one of the more convenient approaches for both the patient and ophthalmologist.Keywords: anti-vascular endothelial growth factor, bilateral intravitreal injection, bevacizumab, aflibercept, ranibizumab, safetyJang KAhn JSohn JHwang DDJDove Medical Pressarticleanti-vascular endothelial growth factorbilateral intravitreal injectionbevacizumabafliberceptranibizumabsafetyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 3211-3218 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-vascular endothelial growth factor bilateral intravitreal injection bevacizumab aflibercept ranibizumab safety Ophthalmology RE1-994
spellingShingle	anti-vascular endothelial growth factor bilateral intravitreal injection bevacizumab aflibercept ranibizumab safety Ophthalmology RE1-994 Jang K Ahn J Sohn J Hwang DDJ Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
description	Kyuhwan Jang,1 Jayoung Ahn,1 Joonhong Sohn,1 Daniel Duck-Jin Hwang1,2 1Department of Ophthalmology, HanGil Eye Hospital, Incheon, Korea; 2Department of Ophthalmology, Catholic Kwandong University College of Medicine, Incheon, KoreaCorrespondence: Daniel Duck-Jin HwangDepartment of Ophthalmology, HanGil Eye Hospital, #35 Bupyeong-Daero, Bupyeong-Gu, Incheon 21388, KoreaTel +82-32-503-3322Fax +82-32-504-3322Email daniel.dj.hwang@gmail.comPurpose: To evaluate the short-term ophthalmic side effects of bilateral same-day intravitreal anti-vascular endothelial growth factor (VEGF) injections.Patients and Methods: We retrospectively analyzed patients who received intravitreal bevacizumab, ranibizumab, and aflibercept injections in both eyes on the same day between January 2014 and June 2019. The patients were followed up for 1 day, 1 week, and 1 month after the injections.Results: A total of 323 patients (646 eyes) received 1418 bilateral same-day intravitreal anti-VEGF injections. The patients’ mean age was 62.47 ± 13.97 years. The most common cause of bilateral injection was age-related macular degeneration (54.80%), followed by complications due to diabetic retinopathy (35.33%), retinal vein occlusion (2.40%), and central serious chorioretinopathy (1.27%). There were 22 cases of subconjunctival hemorrhage, 17 cases of temporary elevation of intraocular pressure, and no case of endophthalmitis. Twenty-one patients showed acute intraocular inflammation after the bilateral injection. All patients showed complete improvement within 2 weeks after the injection.Conclusion: Bilateral same-day intravitreal anti-VEGF injection is a well-tolerated procedure on short-term follow-up. It is one of the more convenient approaches for both the patient and ophthalmologist.Keywords: anti-vascular endothelial growth factor, bilateral intravitreal injection, bevacizumab, aflibercept, ranibizumab, safety
format	article
author	Jang K Ahn J Sohn J Hwang DDJ
author_facet	Jang K Ahn J Sohn J Hwang DDJ
author_sort	Jang K
title	Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
title_short	Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
title_full	Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
title_fullStr	Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
title_full_unstemmed	Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
title_sort	evaluation of the safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents: experience of a large korean retina center
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/6c366e83ca8148b9b6d727ae156d86af
work_keys_str_mv	AT jangk evaluationofthesafetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragentsexperienceofalargekoreanretinacenter AT ahnj evaluationofthesafetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragentsexperienceofalargekoreanretinacenter AT sohnj evaluationofthesafetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragentsexperienceofalargekoreanretinacenter AT hwangddj evaluationofthesafetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragentsexperienceofalargekoreanretinacenter
_version_	1718393629538516992

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center

Ejemplares similares